Login
Research AI
Scans
Tools
Login
Home
Charts
Search
Watchlist
Products
All IPOs

Fabtech Technologies Ltd

TradingIPO
₹191 - 191
₹191 - 191

We are a key turnkey engineering solution provider in pharmaceuticals capex space, offering comprehensive start to finish solutions encompassing designing, engineering, procurement, installation and testing of pharmaceutical equipment for a wide range of customers. (Source: CRISIL Report). We offer services in greenfield projects for a wide range of customers primarily in the pharmaceutical, healthcare and biotech sector across various geographies, particularly key emerging economies. In such projects we offer end to end turnkey engineering services which range from disease identification until installation and commissioning of equipment. Additionally, we also offer some of our engineering solutions, which majorly include, equipment procurement and supply and logistics management, on a standalone basis, either as part of greenfield or brownfield projects. Our Company has adopted an asset light approach wherein we procure key equipment and materials for our projects from Related Entities to ensure that our projects are executed efficiently, to integrate our project execution operations and to reduce our dependence on third party suppliers. Our comprehensive solutions encompasses the entire project lifecycle of our customers and address the three key elements in pharmaceuticals, biotech and healthcare facilities, namely, bio clean air, clean water, and process. In addition to offering targeted solutions across the value chain, we also have an established track record in executing pharmaceutical projects across a diverse range of dosage forms, encompassing, liquids, solids, and semisolids. Our footprint spans more than 62 countries globally and across regions including but not limited to, Middle East, Africa, Asia, Europe, Latin America, North America, etc. (Source: CRISIL Report). Since incorporation and till July 31, 2025, our Company has completed fifty one (51) projects across countries, namely Saudi Arabia, Egypt, Algeria, Bangladesh, Ethiopia, Sri Lanka, United Arab Emirates.

Lot75Min Invest₹14,325Face Value₹10Issue Size₹230 CrFresh Issue₹230 CrListing Price₹191CMP₹120

Timeline

29 Sept
Bidding opens
1 Oct
Bidding closes
3 Oct
Allotment
6 Oct
Refund & demat credit
7 Oct
Listing

Subscription

Subscription opens once dates are announced

Reports

Offer Details

Terms

Issue Size₹230 Cr1.21 Cr shares
Fresh Issue₹230 Cr
Face Value₹10
Lot Size75 shares
ReservationQIB 50% · NII 15% · RETAIL 35%

Application Sizes

Retail₹14,3251-13 lots
sNII₹2,00,550from 14 lots
bNII₹10,02,750from 70 lots

Managers & Registrar

Lead ManagerUnistone Capital Pvt Ltd
RegistrarBigshare Services Pvt Ltd

Ownership & Proceeds

Shareholding

CategoryPre IPOPost IPOPromoter Group94.61%68.94%Public5.39%31.06%

Objects of the Issue

  1. Funding working capital requirements of the company
  2. Pursuing inorganic growth initiatives through acquisitions
  3. General corporate purposes

Financials

Profit & Loss

Financial YearFY23FY24FY25FY26Latest
RevenueCr194226327411418
Operating ProfitCr2534383545
OPM%13.015.011.58.510.9
PBTCr2836604860
PATCr2227463849
EPS78141014

Balance Sheet

Financial YearFY23FY24FY25FY26Latest
Equity CapitalCr333244-
ReservesCr86129141375-
BorrowingsCr35138470-
Fixed AssetsCr--9478-
Total AssetsCr214269427699-

Cash Flow

Financial YearFY23FY24FY25FY26Latest
Operating Cash FlowCr-1460-360-
Investing Cash FlowCr2-30-20-112-
Financing Cash FlowCr12-1236190-
Net Cash FlowCr018-2078-

Strengths & Risks

Strengths · as stated in the DRHP
  • A key turnkey engineering solution provider offering integrated engineering solutions with comprehensive service offerings.
  • Track record of executing projects across all dosage forms.
  • In-house software technology capabilities.
  • Asset-light and integrated business model.
  • Diversified Order Book across geographies, clients, and business verticals.
  • Project execution across diverse and challenging geographies
Show all 8 strengths
Strategies · as stated in the DRHP
  • Expansion in existing regions through our overseas subsidiary or joint ventures to establish local presence.
  • Increase our government clientele in the African region.
  • Pursuing inorganic growth through acquisitions in India, United Arab Emirates, Saudi Arabia and Egypt.
  • Diversify our customer base.
Risks · as stated in the DRHP
  • The actual orders received by our Company during the preceding three Financial Years is less than 11% of the total value of the proposals submitted by us. If we fail to generate leads and convert leads into orders for a prolonged period, our business, financial condition, results of operations, prospects and cash flows could be adversely affected.
  • As a result of our limited operating history, we may not be able to compete successfully, and it may be difficult to evaluate our business and future operating results on the basis of our past performance.
  • Our order book may not be representative of our future results. Projects included in our order book and our future projects may be delayed, modified or cancelled for reasons beyond our control which may materially and adversely affect our business, prospects, reputation, profitability, financial condition and results of operation.
  • We procure a significant portion of our equipment and materials from our Associate, Promoter Group entities and Group Companies. Accordingly, we are dependent upon them to procure the equipment required for executing our projects.
  • We are dependent upon and derive a substantial portion of our revenue from a limited number of projects, that form part of our order book. Cancellation of projects by customers could have a material adverse effect on our business, results of operations and financial condition.
  • We derive majority of our revenue from our turnkey engineering solutions and our financial condition would be materially and adversely affected if we fail to obtain new contracts or our current contracts are terminated.
Show all 87 risks